The United States has both the leverage and the responsibility to ensure that our wealthiest peer nations don’t get unearned discounts on medical advances disproportionately funded by American dollars.
What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually.
The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines.
That may help Germany balance its books. But it comes at a cost to American patients and pharmaceutical innovation. It’s also fundamentally unfair to the United States.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Germany Wants Cheaper Drugs—And Americans To Pay The Difference
Sally C. Pipes
The United States has both the leverage and the responsibility to ensure that our wealthiest peer nations don’t get unearned discounts on medical advances disproportionately funded by American dollars.
What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually.
The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines.
That may help Germany balance its books. But it comes at a cost to American patients and pharmaceutical innovation. It’s also fundamentally unfair to the United States.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.